Gregory A. Otterson
About
Gregory A. Otterson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Gregory A. Otterson has authored 240 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Oncology, 114 papers in Pulmonary and Respiratory Medicine and 81 papers in Molecular Biology. Recurrent topics in Gregory A. Otterson's work include Lung Cancer Treatments and Mutations (93 papers), Lung Cancer Research Studies (50 papers) and Cancer Immunotherapy and Biomarkers (43 papers). Gregory A. Otterson is often cited by papers focused on Lung Cancer Treatments and Mutations (93 papers), Lung Cancer Research Studies (50 papers) and Cancer Immunotherapy and Biomarkers (43 papers). Gregory A. Otterson collaborates with scholars based in United States, Italy and South Korea. Gregory A. Otterson's co-authors include Frederic J. Kaye, Wei‐Guo Zhu, Miguel A. Villalona‐Calero, Erin M. Bertino, Amy Coxon, Robert A. Kratzke, Samir N. Khleif, Christoph Plass, Wenrui Duan and Dwight H. Owen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.
In The Last Decade
Gregory A. Otterson
235 papers receiving 10.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gregory A. Otterson United States | 58 | 5.1k | 5.0k | 3.4k | 1.8k | 875 | 240 | 10.3k | ||
| Carmen Behrens United States | 57 | 5.2k 1.0× | 3.9k 0.8× | 3.0k 0.9× | 2.6k 1.5× | 611 0.7× | 169 | 9.5k | ||
| Susan M. Blaney United States | 63 | 5.0k 1.0× | 3.3k 0.7× | 3.0k 0.9× | 1.2k 0.6× | 841 1.0× | 267 | 11.4k | ||
| Patrick Pauwels Belgium | 60 | 4.3k 0.8× | 4.2k 0.8× | 3.2k 0.9× | 2.9k 1.6× | 724 0.8× | 305 | 10.6k | ||
| Roberto Bianco Italy | 49 | 3.7k 0.7× | 5.0k 1.0× | 3.4k 1.0× | 1.2k 0.7× | 534 0.6× | 208 | 8.9k | ||
| Yoshitaka Sekido Japan | 69 | 9.3k 1.8× | 3.7k 0.7× | 3.6k 1.1× | 3.3k 1.8× | 817 0.9× | 199 | 14.3k | ||
| Alan K. Meeker United States | 57 | 5.2k 1.0× | 3.6k 0.7× | 2.6k 0.8× | 1.6k 0.9× | 773 0.9× | 178 | 11.1k | ||
| Vassilis Georgoulias Greece | 48 | 2.8k 0.5× | 4.9k 1.0× | 2.7k 0.8× | 2.4k 1.3× | 405 0.5× | 296 | 8.3k | ||
| Renato Franco Italy | 50 | 3.4k 0.7× | 3.4k 0.7× | 1.8k 0.5× | 1.6k 0.9× | 829 0.9× | 324 | 8.2k | ||
| Jill M. Siegfried United States | 59 | 4.4k 0.9× | 3.8k 0.8× | 3.8k 1.1× | 1.6k 0.9× | 495 0.6× | 226 | 9.7k | ||
| David M. Jablons United States | 61 | 6.9k 1.4× | 4.8k 1.0× | 5.2k 1.5× | 2.0k 1.1× | 608 0.7× | 273 | 14.2k |
Countries citing papers authored by Gregory A. Otterson
Since
Specialization
Citations
This map shows the geographic impact of Gregory A. Otterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Otterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Otterson more than expected).
Fields of papers citing papers by Gregory A. Otterson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gregory A. Otterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Otterson. The network helps show where Gregory A. Otterson may publish in the future.
Co-authorship network of co-authors of Gregory A. Otterson
This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Otterson. A scholar is included among the top collaborators of Gregory A. Otterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Otterson. Gregory A. Otterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Riely, Gregory J., Egbert F. Smit, Myung‐Ju Ahn, et al.. (2023). Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.. Journal of Clinical Oncology. 41(16_suppl). 9018–9018.
2.
Villaruz, Liza C., George R. Blumenschein, Gregory A. Otterson, & Ticiana Leal. (2023). Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer. Cancer. 129(9). 1319–1350.
3.
Wang, X., Erin M. Bertino, Scott Antonia, et al.. (2023). A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. ESMO Open. 8(2). 101183–101183.
4.
Welliver, M.X., et al.. (2023). A Case of Mediastinal Carcinosarcoma With Beta-HCG Production and KRAS Mutation. International Journal of Surgical Pathology. 31(8). 1598–1604.
5.
Boyer, Michael, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, et al.. (2021). Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology. 39(21). 2327–2338.
6.
Li, Mingjia, Daniel Spakowicz, Jarred Burkart, et al.. (2019). Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. Journal of Cancer Research and Clinical Oncology. 145(10). 2541–2546.
7.
Miller, Eric D., James L. Fisher, Karl Haglund, et al.. (2018). Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiation Oncology. 13(1). 196–196.
8.
Drilon, Alexander, Jeffrey W. Clark, Jared Weiss, et al.. (2018). OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S348–S348.
9.
Miller, Eric D., James L. Fisher, Kaisa Haglund, et al.. (2018). Racial/Ethnic Disparities in the Delivery of Curative Intent Therapy in Patients with Stage III Non-small Cell Lung Cancer Not Treated Surgically: An Analysis of the National Cancer Database. International Journal of Radiation Oncology*Biology*Physics. 102(3). e410–e410.
10.
Bertino, Erin M., Elizabeth L. McMichael, Xiaokui Mo, et al.. (2016). A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. Molecular Cancer Therapeutics. 15(9). 2244–2250.
11.
Burkart, Jarred, et al.. (2015). Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations. SHILAP Revista de lepidopterología. 2015. 1–4.
12.
Martin, Ludmila Katherine, Gregory A. Otterson, & Tanios Bekaii‐Saab. (2012). Photodynamic Therapy (PDT) May Provide Effective Palliation in the Treatment of Primary Tracheal Carcinoma: A Small Case Series. Photomedicine and Laser Surgery. 30(11). 668–671.
13.
Bertino, Erin M., et al.. (2010). Small Cell Lung Cancer in Never Smokers: Report of Two Cases. Journal of Thoracic Oncology. 5(5). 747–748.
14.
Herbst, Roy S., Howard M. Stern, Lukas C. Amler, et al.. (2009). Abstract #LB-131: Biomarker evaluation in the Phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes. Cancer Research. 69.
15.
Au, Jessie L.‐S., Thomas Olencki, M. Guillaume Wientjes, et al.. (2007). P2-230: A Phase I Study of Nontoxic Suramin As A Chemosensitizer In Pretreated/Refractory Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 2(8). S663–S664.
16.
Smith, Laura T., Romulo Martin Brena, James C. Lang, et al.. (2006). Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proceedings of the National Academy of Sciences. 103(4). 982–987.
17.
Mauer, Ann M., Gregory A. Otterson, Charles M. Rudin, et al.. (2004). A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Annals of Oncology. 15(6). 915–920.
18.
Otterson, Gregory A., et al.. (1998). Protein Expression and Functional Analysis of the FHIT Gene in Human Tumor Cells. JNCI Journal of the National Cancer Institute. 90(6). 426–432.
19.
Otterson, Gregory A., Brian P. Monahan, Nancy Harold, et al.. (1996). Clinical significance of the FV:Q506 mutation in unselected oncology patients. The American Journal of Medicine. 101(4). 406–412.
20.
Nikliński, Jacek, et al.. (1995). The N-Terminal Domain of c-Myc Associates with α-Tubulin and Microtubules In Vivo and In Vitro. Molecular and Cellular Biology. 15(9). 5188–5195.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Carmen Behrens Breakdown of academic impact, for papers by Susan M. Blaney Breakdown of academic impact, for papers by Patrick Pauwels Breakdown of academic impact, for papers by Roberto Bianco Breakdown of academic impact, for papers by Yoshitaka Sekido Breakdown of academic impact, for papers by Alan K. Meeker Breakdown of academic impact, for papers by Vassilis Georgoulias Breakdown of academic impact, for papers by Renato Franco Breakdown of academic impact, for papers by Jill M. Siegfried Breakdown of academic impact, for papers by David M. Jablons